Key Metrics of CollPlant Biotechnologies Ltd
Revenue$11.0M▲ 3,565.2% YoYFY 2023
Operating income−$7.5M▲ 56.1% YoY
Net profit−$7.0M▲ 58.5% YoY
Shareholders' equity$28.3M
Market cap$10.4MCLGN · $3.62
Competitors10identified
About CollPlant Biotechnologies Ltd
Sectors
Company details
- Listed
- Nasdaq: CLGN
Operational Areas of CollPlant Biotechnologies Ltd
Pharmaceuticals & Healthcare›Biotechnology & Vaccines
Company summary
Legal nameCollPlant Biotechnologies Ltd
TickerCLGN
ExchangeNasdaq
CountryIsrael
SEC CIK0001631487
Listed since—
IndustryIndustrial Specialties
SectorPharmaceuticals & Healthcare · Biotechnology & Vaccines
Website—
US market & SEC filings
CLGN · Nasdaq · SEC CIK 0001631487
Last price · 23 Oct 2026
$3.62
−3.60%
Market cap$10.4M
P/E—On FY 2023 diluted EPS
Volume10,613
SectorHealth CareIndustrial Specialties
Country · IPOIsrael
CLGN share price
Premium
Annual results (SEC EDGAR)
Revenue, operating income, net income, EPS, cash flow, assets, liabilities, equity and debt for every year filed with the SEC are part of the premium plan.
Sign in to continue See plans & pricingVendor checks & payment capacity
Sign in with access to company financials to review vendor evidence.
Registered office and contact
Registered office—
GSTIN—
Email—
Website—
Members / shareholders—
Directors and key people
Directors are read from the MGT-7 annual return and AOC-4 signatories.
Competitors of CollPlant Biotechnologies Ltd
Competitors10identified
Countries2most in United States
Top competitors by location
| Company | Description | Domain | Founded | Location |
|---|---|---|---|---|
| Part of Vertex Pharmaceuticals. | vrtx.com | 1991 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | gsk.com | 2022 | United Kingdom | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | modernatx.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | bd.com | — | United States | |
| Part of Illumina. | illumina.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | guardanthealth.com | 2018 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | revvity.com | — | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | exelixis.com | 2000 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | neurocrine.com | 1996 | United States | |
| Biotechnology & Vaccines · Pharmaceuticals & Healthcare | biomarin.com | 1999 | United States |
Charges (secured borrowings)
0 registered charges. Lenders, amounts and dates are part of the premium plan.
Statutory auditors
Auditors are read from the AOC-4 auditor's report section.
Business activities and related parties
Principal business activities and related-party transactions are read from MGT-7 and AOC-4 filings.
Filings
No filings on record yet.